Ubs Group Ag Relmada Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
49Shares Held
6.3MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$871,8280.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$857,7330.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$407,0520.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$351,5530.03% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$214,3360.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $20.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...